Efficacy of kallidinogenase for clinically significant macular edema with diabetic retinopathy

Efficacy of kallidinogenase for clinically significant macular edema with diabetic retinopathy - Efficacy of kallidinogenase for CSME

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005339

Enrollment

Registered

2011-04-01

Start date

2011-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic retinopathy

Interventions

Kallidinogenase(+) 20 cases Kallidinogenase(-) 20 cases

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient whose age is 20 years old or more when agreement is acquired. Patient who obtained agreement after enough explanation when participating in this study is received.

Exclusion criteria

Exclusion criteria: Patient with freshness bleeding immediately after erebral hemorrhage. Patient who are allergic to kallidinogenase. Patient with poor control of blood sugar level, in brief HbA1c is above 10%. Patient with renal failure, in brief Cr is above 3mg/dl. Patient who is judged inappropriate for study.

Design outcomes

Primary

Measure	Time frame
We examine the effect on the central macular thickness, visual acuity, blood flow of the ocular fundus, and the thickness of the choroid for 3 months, and evaluate the recurrence of edema after 3months.	—

Countries

Japan

Contacts

Public ContactEIKO TSUIKI

NAGASAKI UNIVERSITY HOSPITAL Ophthalmology

t-eiko@nagasaki-u.ac.jp0958197345

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026